



**Vaccines and Global Health: The Week in Review**  
**12 January 2019**  
**Center for Vaccine Ethics & Policy (CVEP)**

*This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.*

*Vaccines and Global Health: The Week in Review is also **posted in pdf form** and as a set of blog posts at <https://centerforvaccineethicsandpolicy.net>. This blog allows full-text searching of over 8,000 entries.*

*Comments and suggestions should be directed to*

*David R. Curry, MS*

*Editor and*

*Executive Director*

*Center for Vaccine Ethics & Policy*

*[david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)*

***Request an email version:*** *Vaccines and Global Health: The Week in Review is published as a single email summary, scheduled for release each Saturday evening at midnight (EST/U.S.). If you would like to receive the email version, please send your request to [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org).*

***Support this knowledge-sharing service:*** *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

**Contents** *[click on link below to move to associated content]*

A. [Milestones :: Perspectives :: Featured Journal Content](#)

B. [Emergencies](#)

C. [WHO; CDC \[U.S., Africa, China\]](#)

D. [Announcements](#)

E. [Journal Watch](#)

F. [Media Watch](#)

## Milestones :: Perspectives

.....  
.....

### **[Global Fund Announces US\\$14 Billion Target to Step Up the Fight Against AIDS, TB and Malaria Ahead of Lyon Conference in October 2019](#)**

11 January 2019

PARIS – The Global Fund today announced its fundraising target for the next three-year cycle, outlining how a minimum of US\$14 billion will help save 16 million lives, cut the mortality rate from HIV, TB and malaria in half, and build stronger health systems by 2023. The summary of the Sixth Replenishment Investment Case describes what can be achieved by a fully funded Global Fund, the new threats facing global health progress today, and the risks if we don't step up the fight now.

French President Emmanuel Macron expressed his strong support for the Global Fund's replenishment target today. Joined in Paris by Global Fund Executive Director Peter Sands, World Health Organization Director-General Dr. Tedros Adhanom Ghebreyesus, and French Minister of Solidarity and Health Agnes Buzyn, President Macron stressed the need for global collaboration to end the epidemics. France is a founding member of the Global Fund and will host the Global Fund's Sixth Replenishment Conference in Lyon on 10 October 2019.

"We must relaunch efforts to fight health inequalities at the international level," said President Macron. "We are hosting the Sixth Replenishment Conference of the Global Fund to Fight AIDS, Tuberculosis and Malaria in Lyon in 2019. We will step up our action to tackle the major pandemics. I call on everyone here to mobilize."...

The full Global Fund Sixth Replenishment Investment Case will be presented and discussed by global health leaders at the Preparatory Meeting of the Global Fund Sixth Replenishment, hosted by the government of India in New Delhi on 8 February 2019.

[Sixth Replenishment Investment Case](#) [Summary – PDF]

.....  
.....

### **[144th Session of the WHO Executive Board](#)**

24 January – 1 February 2019 Coordinated Universal Time  
Geneva, Switzerland

*Selected Agenda Content*

[EB144/1](#) - Provisional agenda

[EB144/1 \(annotated\)](#) - Provisional agenda (annotated)

[EB144/8](#) - Public health preparedness and response

Report of the Independent Oversight and Advisory Committee for the WHO Health Emergencies Programme

[EB144/9](#) – Polio Eradication

[EB144/10](#) – Polio Transition

[EB144/11 Rev.1](#) - Implementation of the 2030 Agenda for Sustainable Development

[EB144/12](#) - Universal health coverage

Primary health care towards universal health coverage

[EB144/13](#) - Universal health coverage

Community health workers delivering primary health care: opportunities and challenges

[EB144/14](#) - Universal health coverage

Preparation for the high-level meeting of the United Nations General Assembly on universal health coverage

[EB144/17](#) - Medicines, vaccines and health products

Access to medicines and vaccines

[EB144/18](#) - Medicines, vaccines and health products

Cancer medicines

[EB144/19](#) - Follow-up to the high-level meetings of the United Nations General Assembly on health-related issues

Antimicrobial resistance

[EB144/21](#) - Follow-up to the high-level meetings of the United Nations General Assembly on health-related issues

Ending tuberculosis

[EB144/23](#) - Pandemic Influenza Preparedness Framework for the sharing of influenza viruses and access to vaccines and other benefits

Implementation of decision WHA71(11) (2018)

[EB144/24](#) - Member State mechanism on substandard and falsified medical products

[EB144/27](#) - Promoting the health of refugees and migrants

Draft global action plan, 2019–2023

.....  
.....

## **Ebola - Democratic Republic of the Congo**

### **23: Situation report on the Ebola outbreak in North Kivu**

8 January 2019 [*Excerpts*]

#### **...*Case management***

On 24 November 2018, MoH announced the launch of a randomized control trial for Ebola therapeutics. This first-ever multi-drug randomized control trial within an outbreak setting, is an important step towards finding an effective evidence-based treatment for Ebola. The trial is coordinated by WHO and led and sponsored by the Democratic Republic of the Congo's National Institute for Biomedical Research (INRB) which is the principal investigator. The trial has begun in the Alliance for International Medical Action (ALIMA) ETC in Beni, where patients are enrolled

in the study after obtaining voluntary informed consent. MSF treatment centres are also preparing to launch the trial at their sites in the near future.

Until other ETCs are ready to launch the trial, they will continue to provide therapeutics under the Monitored Emergency Use of Unregistered Interventions (MEURI) (compassionate use) protocol, in collaboration with the MoH and the INRB, together with supportive care measures. WHO continues to provide technical clinical expertise on-site at all treatment centres. UNICEF is providing nutritional treatment and psychological support for all hospitalized patients.

As of 6 January 2019, a total of 151 patients are hospitalized in ETCs, of which 29 are confirmed cases, receiving compassionate therapy.

As of 4 January 2019, Katwa ETC has been opened and admitted three suspected cases.

### ***...Implementation of ring vaccination protocol***

As of 6 January 2019, a total of 56,509 individuals have been vaccinated since the start of the outbreak.

.....

**DONs [Ebola virus disease – Democratic Republic of the Congo](#)** 10 January 2019

*[Excerpt]*

### ***...WHO risk assessment***

*Unchanged: "...risk of national and regional spread is very high"*

.....

.....

## **Emergencies**

### **POLIO**

*Public Health Emergency of International Concern (PHEIC)*

### **Polio this week as of 08 January 2019**

:: During the four-day visit to polio endemic countries of Afghanistan and Pakistan, WHO Director General, Dr Tedros Adhanom Ghebreyesus, reiterated WHO's commitment to help endemic, outbreak and at-risk countries rid of poliovirus. Read the press release [here](#).

:: In Mozambique, a circulating vaccine-derived poliovirus type 2 (cVDPV2) outbreak is confirmed.

*Summary of new viruses this week:*

:: **Afghanistan** – two WPV1-positive environmental samples;

:: **Pakistan** – nine WPV1-positive environmental samples;

:: **Mozambique** - one new case of cVDPV2.

### **WHO DG calls for concerted efforts to end polio during his visit to Pakistan and Afghanistan**

10/01/2019

*Endemic countries, WHO and partners are committed to eradicate polio*

For Dr Tedros Adhanom Ghebreyesus, Director-General of WHO, the start to the new year was marked with a four-day visit to Afghanistan and Pakistan from 5-8 January. The visit came at the heels of his new role as the Chair of the [Polio Oversight Board \(POB\)](#) on 1 January, a committee which oversees and guides the Global Polio Eradication Initiative, signalling the Board's utmost commitment towards eradication of polio for good.

Accompanied by WHO Regional Director for the Eastern Mediterranean Dr Ahmed Al-Mandhari, Dr Tedros' well-knit, compact visit covered a lot of bases from field visits to high-level meetings with heads of state from both the countries, giving the POB an opportunity to see that while polio may still be in endemic in Afghanistan and Pakistan, but the process to achieve the goal of ending polio is not far from realization.

"We must all give our best on this last mile to eradicate polio once and for all. My wish for 2019 is for zero polio transmission. You have WHO's full support to help reach every child and stop this virus for good," Dr Tedros said...

.....  
.....

***Editor's Note:***

*WHO has posted a [refreshed emergencies page](#) which presents an updated listing of Grade 3,2,1 emergencies as below.*

**[WHO Grade 3 Emergencies](#)** [to 12 Jan 2019]

**[Democratic Republic of the Congo](#)**

:: [23: Situation report on the Ebola outbreak in North Kivu](#) 8 January 2019

:: [DONs Ebola virus disease – Democratic Republic of the Congo](#) 10 January 2019

*[See Milestones above for more detail]*

[Bangladesh - Rohingya crisis](#) - *No new announcements identified*

[Myanmar](#) - *No new announcements identified*

[Nigeria](#) - *No new announcements identified*

[Somalia](#) - *No new announcements identified*

[South Sudan](#) - *No new announcements identified*

[Syrian Arab Republic](#) - *No new announcements identified*

[Yemen](#) - *No new announcements identified*

.....

**[WHO Grade 2 Emergencies](#)** [to 12 Jan 2019]

[occupied Palestinian territory](#) - *No new announcements identified*

[Brazil \(in Portuguese\)](#) - *No new announcements identified*

[Cameroon](#) - *No new announcements identified*

[Central African Republic](#) - *No new announcements identified*

[Ethiopia](#) - *No new announcements identified*

[Hurricane Irma and Maria in the Caribbean](#) - *No new announcements identified*

[Iraq](#) - *No new announcements identified*

[Libya](#) - *No new announcements identified*

[MERS-CoV](#) - *No new announcements identified*

Niger - *No new announcements identified*  
Sao Tome and Principe Necrotizing Cellulitis (2017) - *No new announcements identified*  
Sudan - *No new announcements identified*  
Ukraine - *No new announcements identified*  
Zimbabwe - *No new announcements identified*

.....

### **WHO Grade 1 Emergencies** [to 12 Jan 2019]

Afghanistan  
Chad  
Indonesia - Sulawesi earthquake 2018  
Kenya  
Lao People's Democratic Republic  
Mali  
Namibia - viral hepatitis  
Peru  
Philippines - Typhoon Mangkhut  
Tanzania

.....

.....

### **UN OCHA – L3 Emergencies**

*The UN and its humanitarian partners are currently responding to three 'L3' emergencies. This is the global humanitarian system's classification for the response to the most severe, large-scale humanitarian crises.*

Syrian Arab Republic - *No new announcements identified*  
Yemen - *No new announcements identified*

.....

### **UN OCHA – Corporate Emergencies**

*When the USG/ERC declares a Corporate Emergency Response, all OCHA offices, branches and sections provide their full support to response activities both at HQ and in the field.*

Ethiopia - *No new announcements identified*  
Somalia - *No new announcements identified*

.....

### **"Other Emergencies"**

Indonesia: Central Sulawesi Earthquake - *No new announcements identified*

.....

.....

***Editor's Note:***

*We will cluster these recent emergencies as below and continue to monitor the WHO webpages for updates and key developments.*

**EBOLA/EVD** [to 12 Jan 2019]

<http://www.who.int/ebola/en/>

:: 23: Situation report on the Ebola outbreak in North Kivu 8 January 2019

:: DONs Ebola virus disease – Democratic Republic of the Congo 10 January 2019

*[See Milestones above for more detail]*

**MERS-CoV** [to 12 Jan 2019]

<http://who.int/emergencies/mers-cov/en/>

- *No new announcements identified.*

**Yellow Fever** [to 12 Jan 2019]

<http://www.who.int/csr/disease/yellowfev/en/>

- *No new announcements identified.*

**Zika virus** [to 12 Jan 2019]

<http://www.who.int/csr/disease/zika/en/>

- *No new announcements identified.*

.....  
.....

**WHO & Regional Offices** [to 12 Jan 2019]

**[“Zero polio transmission and health for all”, WHO Director-General gives new year’s wish to the people of Afghanistan and Pakistan](#)**

8 January 2019 *News Release*

WHO Director-General Dr Tedros Adhanom Ghebreyesus highlighted WHO’s commitment to the final push to eradicate polio on a 4-day visit to Afghanistan and Pakistan - the only two countries where wild poliovirus cases were reported last year. He also commended the governments of both countries for their efforts to provide universal access to health services...

.....

**[144th Session of the WHO Executive Board](#)**

24 January – 1 February 2019 Coordinated Universal Time

Geneva, Switzerland

*[See selected agenda content in Milestones above]*

.....

**[Weekly Epidemiological Record, 11 January 2019, vol. 94, 01/02 \(pp. 1–16\)](#)**

:: Meeting of the International Task Force for Disease Eradication, April 2018

:: Immunization and Vaccine-related Implementation Research Advisory Committee (IVIR-AC) recommendations September 2018

.....

## **WHO Regional Offices**

*Selected Press Releases, Announcements*

### **WHO African Region AFRO**

*Selected Featured News*

:: [New Hope with Ebola Drug Trial](#) 11 January 2019

### **WHO Region of the Americas PAHO**

*- No new announcement identified*

### **WHO South-East Asia Region SEARO**

:: Polio-free WHO South-East Asia Region

Sanjit Das

On 13 January this year WHO South-East Asia Region marks eight years since the last case of wild poliovirus.

The Region continues to be polio-free due to ongoing efforts by member countries, partners and the people themselves to ensure all children are protected with polio vaccines.

A strict vigil is being maintained against polioviruses.

### **WHO European Region EURO**

:: [Close collaboration yields progress on TB prevention and care in the Russian Federation](#) 09-01-2019

### **WHO Eastern Mediterranean Region EMRO**

:: [WHO delivers medical supplies to support emergency health care in north-east Syria](#) 9 January 2019

:: [WHO Director-General visits Afghanistan for continued efforts on polio eradication and health financing](#) 5 January 2019

### **WHO Western Pacific Region**

*- No new announcement identified*

.....

.....

**CDC/ACIP** [to 12 Jan 2019]

<http://www.cdc.gov/media/index.html>

<https://www.cdc.gov/vaccines/acip/index.html>

Friday, January 11, 2019

### **[CDC Provides First In-Season Estimates of Flu Illnesses, Medical Visits, and Hospitalizations](#)**

According to [new data](#) released by CDC, so far during the 2018-2019 season between about 6 and 7 million people have been sick with flu, up to half of those people have sought medical care for their illness, and between 69,000 and 84,000 people have been hospitalized from flu. This is the first time these estimates— which cover the period from October 1, 2018 through January 5, 2019— are being provided during the flu season. CDC has estimated the [burden of flu](#) since 2010...



## **MMWR News Synopsis for Friday, January 1, 2019**

### **Establishing a Baseline for Cervical Cancer Screening Coverage — India, 2015–2016**

Among women ages 30-49, fewer than one in three Indian women in the age range for screening for cervical cancer reported having been screened. Measuring cervical cancer screening and identifying socioeconomic factors associated with the acceptance of screening can be used to plan targeted interventions, screening campaigns, and evaluation to help India meet the goal of universal cervical cancer screening. Cervical cancer is the second leading cause of new cancer cases among women in India. In 2016, the Ministry of Health and Family Welfare of India recommended population-based cervical cancer screening for all women ages 30-65 years. In 2015-16, for the first time, one of the largest national surveys (over 700,000 women) conducted in India asked reproductive-aged women if they had ever been screened for cervical cancer. Fewer than one in three Indian women (ages 30-49) reported having been screened for cervical cancer. There was substantial geographic variation, and screening rates were higher among women with more education, greater wealth, and who had ever been married.

.....

**Africa CDC** [to 12 Jan 2019]

<https://au.int/en/africacdc>

*No new digest content identified.*

.....

**China CDC**

<http://www.chinacdc.cn/en/>

*New website launched...no "news" or "announcements" page identified.*

**National Health Commission of the People's Republic of China**

<http://en.nhfpc.gov.cn/>

*Selected Updates/ Press Releases/ Notices*

*No new digest content identified.*

.....

.....

### **Announcements**

**BMGF - Gates Foundation** [to 12 Jan 2019]

<http://www.gatesfoundation.org/Media-Center/Press-Releases>

*No new digest content identified.*

**Bill & Melinda Gates Medical Research Institute** [to 12 Jan 2019]

<https://www.gatesmri.org/>

*The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three*

*major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people*  
*No new digest content identified.*

**CARB-X** [to 12 Jan 2019]

<https://carb-x.org/>

*CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.*

*No new digest content identified.*

**CEPI – Coalition for Epidemic Preparedness Innovations** [to 12 Jan 2019]

<http://cepi.net/>

Posted on 07TH JAN 2019 by Mario Christodoulou

**[CEPI launches call for proposals to develop vaccines against Rift Valley fever and Chikungunya viruses](#)**

OSLO (Norway)

The Coalition for Epidemic Preparedness Innovations (CEPI) has launched a call for proposals to develop human vaccines against Rift Valley fever and Chikungunya viruses. This will be CEPI's third call for proposals since January, 2017. USD\$ 48 million of funding will be made available through this call and it is expected to fund up to eight projects.

The broadening of CEPI's vaccine portfolio to include Rift Valley fever and Chikungunya viruses has been based on wide consultation and advice from CEPI's Scientific Advisory Committee and on three main criteria: the public health impact of these diseases, that no vaccines are currently available for human use, and the feasibility of vaccine development.

This opportunity will be open, worldwide, to research and development organisations with expertise in vaccine development. The closing date for funding applications is March 5, 2019...

**EDCTP** [to 12 Jan 2019]

<http://www.edctp.org/>

*The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials*

*Latest news*

*No new digest content identified.*

**Emory Vaccine Center** [to 12 Jan 2019]

<http://www.vaccines.emory.edu/>

*No new digest content identified.*

**European Medicines Agency** [to 12 Jan 2019]

<http://www.ema.europa.eu/ema/>

*News and press releases*  
*No new digest content identified.*

**European Vaccine Initiative** [to 12 Jan 2019]

<http://www.euvaccine.eu/news-events>

*No new digest content identified.*

**FDA** [to 12 Jan 2019]

January 07, 2019

[Statement from FDA Commissioner Scott Gottlieb, M.D., on the agency's new actions under the Pre-Cert Pilot Program to promote a more efficient framework for the review of safe and effective digital health innovations](#)

**Fondation Merieux** [to 12 Jan 2019]

<http://www.fondation-merieux.org/>

*Mérieux Foundation co-organized event*

[Dengue pre-vaccination screening based on serostatus: rapid tests and implementation strategies](#)

January 14 - 16, 2019 - Les Pensières Center for Global Health, Veyrier du Lac (France)

**Gavi** [to 12 Jan 2019]

<https://www.gavi.org/>

*No new digest content identified.*

**GHIT Fund** [to 12 Jan 2019]

<https://www.ghitfund.org/newsroom/press>

*GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that devastate the world's poorest people. Other funders include six Japanese pharmaceutical*

*No new digest content identified.*

**Global Fund** [to 12 Jan 2019]

<https://www.theglobalfund.org/en/news/>

11 January 2019

[Global Fund Announces US\\$14 Billion Target to Step Up the Fight Against AIDS, TB and Malaria Ahead of Lyon Conference in October 2019](#)

*[See Milestones above for detail]*

**Hilleman Laboratories** [to 12 Jan 2019]

<http://www.hillemanlabs.org/>

*No new digest content identified.*

**Human Vaccines Project** [to 12 Jan 2019]

<http://www.humanvaccinesproject.org/media/press-releases/>

*No new digest content identified.*

**IAVI** [to 12 Jan 2019]

<https://www.iavi.org/newsroom>

*No new digest content identified.*

**IFFIm**

<http://www.iffim.org/library/news/press-releases/>

*No new digest content identified.*

**IVAC** [to 12 Jan 2019]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

*No new digest content identified.*

**IVI** [to 12 Jan 2019]

<http://www.ivi.int/>

*IVI News & Announcements*

January 4, 2019

[\*\*IVI Director General addresses 'neglected diseases' in STAT News\*\*](#)

**JEE Alliance** [to 12 Jan 2019]

<https://www.jeealliance.org/>

*No new digest content identified.*

**MSF/Médecins Sans Frontières** [to 12 Jan 2019]

<http://www.msf.org/>

*Selected News; Project Updates, Reports*

*No new digest content identified.*

**NIH** [to 12 Jan 2019]

<http://www.nih.gov/news-events/news-releases>

January 10, 2019

[\*\*The science is clear: with HIV, undetectable equals untransmittable\*\*](#)

— NIH officials discuss scientific evidence and principles underlying the U=U concept.

ARTICLE: RW Eisinger, CW Dieffenbach, AS Fauci. HIV viral load and transmissibility of HIV infection: undetectable equals untransmittable. *Journal of the American Medical Association* DOI: 10.1001/jama.2018.21167 (2019).

January 10, 2019

**[AI approach outperformed human experts in identifying cervical precancer](#)**

— Algorithm could revolutionize cervical cancer screening, especially in low-resource settings

**PATH** [to 12 Jan 2019]

<https://www.path.org/media-center/>

*No new digest content identified.*

**Sabin Vaccine Institute** [to 12 Jan 2019]

<http://www.sabin.org/updates/pressreleases>

*No new digest content identified.*

**UNAIDS** [to 12 Jan 2019]

<http://www.unaids.org/en>

*Selected Press Releases/Reports/Statements*

10 January 2019

**[Traversing rivers and jungles to reach indigenous peoples in remote parts of Brazil](#)**

Indigenous health worker Jijuké Hukanaru Karajá works as a nurse in the Indigenous Health District of Araguaia, named after one of Brazil's major rivers located in the eastern Amazon basin. She has been working with indigenous peoples for many years and criss-crosses between Brazil's cities and indigenous villages to provide crucial health services. Ms Karajá feels very proud to be a part of the Brazilian indigenous public health system, having followed in her father's footsteps...

**UNICEF** [to 12 Jan 2019]

<https://www.unicef.org/media/press-releases>

*Selected Press Releases/Reports/Statements*

*No new digest content identified.*

**Vaccine Confidence Project** [to 12 Jan 2019]

<http://www.vaccineconfidence.org/>

*No new digest content identified.*

**Vaccine Education Center – Children's Hospital of Philadelphia** [to 12 Jan 2019]

<http://www.chop.edu/centers-programs/vaccine-education-center>

*No new digest content identified.*

**Wellcome Trust** [to 12 Jan 2019]

<https://wellcome.ac.uk/news>

*No new digest content identified.*

**The Wistar Institute** [to 12 Jan 2019]  
<https://www.wistar.org/news/press-releases>

*Press Release*

Jan. 8, 2019

**[First-in-Class DNA-encoded Monoclonal Antibody Therapy Rapidly Advances into the Clinic](#)**

*Multisector collaboration yields first-in-human clinical trial for testing novel Zika antibody therapy.*

**World Organisation for Animal Health (OIE)** [to 12 Jan 2019]  
<http://www.oie.int/en/for-the-media/press-releases/2018/>

*No new digest content identified.*

::::::

**BIO** [to 12 Jan 2019]  
<https://www.bio.org/insights/press-release>  
Jan 11 2019

**[BIO Applauds House Passage of the Pandemic and All-Hazards Preparedness and Advancing Innovation Act](#)**

"Members of the House have sent a strong signal to the American people about their commitment to prioritizing health security by providing the resources needed to fully prepare for and defend against biological threats. Strengthening the pipeline of medical products, drugs and devices that will safeguard the nation during an emergency or pandemic is vital to our national security."

**DCVMN – Developing Country Vaccine Manufacturers Network** [to 12 Jan 2019]  
<http://www.dcvmn.org/>

*No new digest content identified.*

**IFPMA** [to 12 Jan 2019]  
<http://www.ifpma.org/resources/news-releases/>  
10 January 2019

**[R&D biopharmaceutical industry embraces NEW Code of Practice to boost business integrity worldwide](#)**

*:: The new Code of Practice in place from 1 January 2019, imposes a complete ban on gifts and promotional aids*

*:: Industry moves beyond compliance and reaffirms its commitment to ensuring an ethical framework as a way to increase integrity and trust*

*:: Industry presents new Code to patients and healthcare professionals*

**PhRMA** [to 12 Jan 2019]  
<http://www.phrma.org/press-room>

*No new digest content identified.*

\* \* \* \*

### ***Journal Watch***

*Vaccines and Global Health: The Week in Review* continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)

### **American Journal of Infection Control**

January 2019 Volume 47, Issue 1, p1-116

<http://www.ajicjournal.org/current>

[Reviewed earlier]

### **American Journal of Preventive Medicine**

January 2019 Volume 56, Issue 1, p1-178

<http://www.ajpmonline.org/current>

[Reviewed earlier]

### **American Journal of Public Health**

January 2019 109(1)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

### **American Journal of Tropical Medicine and Hygiene**

Volume 100, Issue 1, 2019

<http://www.ajtmh.org/content/journals/14761645/100/1>

[New issue; No digest content identified]

### **Annals of Internal Medicine**

1 January 2019 Vol: 170, Issue 1

<http://annals.org/aim/issue>

[Reviewed earlier]

### **BMC Cost Effectiveness and Resource Allocation**

<http://resource-allocation.biomedcentral.com/>

(Accessed 12 Jan 2019)  
[No new digest content identified]

### **BMJ Global Health**

January 2019 - Volume 4 - 1  
<https://gh.bmj.com/content/4/1>  
[Reviewed earlier]

### **BMC Health Services Research**

<http://www.biomedcentral.com/bmchealthservres/content>  
(Accessed 12 Jan 2019)

*Debate*

#### **[Research ethics oversight in Norway: structure, function, and challenges](#)**

*While the development and evaluation of clinical ethics services in Norway has been recognized internationally, the country's research ethics infrastructure at times may have been less well developed. In 2016, media interest in the controversial nature of some health services research and pilot studies highlighted gaps in the system with certain types of research having no clear mechanisms through which they may be given due independent consideration. It is not clear that new legislation, implemented in 2017, will address this problem.*

Authors: R. Froud, T. J. Meza, K. O. Ernes and A. M. Slowther

Citation: BMC Health Services Research 2019 19:24

Published on: 10 January 2019

### **BMC Infectious Diseases**

<http://www.biomedcentral.com/bmcinfectdis/content>  
(Accessed 12 Jan 2019)

*Research article*

#### **[Rates of hospitalization and death for all-cause and rotavirus acute gastroenteritis before rotavirus vaccine introduction in Kenya, 2010–2013](#)**

*Rotavirus vaccine was introduced in Kenya immunization program in July 2014. Pre-vaccine disease burden estimates are important for assessing vaccine impact.*

Authors: Richard Omore, Sammy Khagayi, Billy Ogwel, Reuben Onkoba, John B. Ochieng, Jane Juma, Stephen Munga, Collins Tabu, Sergon Kibet, J. Pekka Nuorti, Frank Odhiambo, Jason M. Mwenda, Robert F. Breiman, Umesh D. Parashar and Jacqueline E. Tate

Citation: BMC Infectious Diseases 2019 19:47

Published on: 11 January 2019

### **BMC Medical Ethics**

<http://www.biomedcentral.com/bmcmedethics/content>  
(Accessed 12 Jan 2019)

*Research article*

#### **[Participants' awareness of ethical compliance, safety and protection during participation in pharmaceutical industry clinical trials: a controlled survey](#)**



Authors: Gerardo González-Saldivar, René Rodríguez-Gutiérrez, Jose Luis Viramontes-Madrid, Alejandro Salcido-Montenegro, Neri Alejandro Álvarez-Villalobos, Victoria González-Nava and José Gerardo González-González

Citation: BMC Medical Ethics 2019 20:2

Published on: 8 January 2019

### *Abstract*

#### Background

The rapid increase of industry-sponsored clinical research towards developing countries has led to potentially complex ethical issues to assess. There is scarce evidence about the perception of these participants about the ethical compliance, security, and protection. We sought to evaluate and contrast the awareness and perception of participants and non-participants of industry-sponsored research trials (ISRT) on ethical, safety, and protection topics.

#### Methods

A Cases-control survey conducted at twelve research sites in México. Previous and current participants of ISRT (cases) as well as non-participants (controls) with one of four chronic diseases, were asked to complete the survey which focused on ethical compliance and protection issues of ISRT, and the perception of participating in a trial.

#### Results

A total of 604 cases and 604 controls were surveyed. Cases significantly answered that ethics committees are aware of what is happening in studies (50.5% vs. 33.8%,  $P = \leq 0.001$ ), and that medical care of industry-sponsored research trials is better than their usual medical care (77.2% vs. 38.2%,  $P = < 0.001$ ). The same proportion of cases and controls thought patients must receive economical reimbursement for participating in a research study (49.5% vs. 53.1%,  $P = 0.205$ ). The informed consent of the pharmaceutical clinical trial was fully read by 90.4% of the cases. Most cases were satisfied or very satisfied with their overall study participation (35.6 and 62.3%, respectively).

#### Conclusion

Previous and current participants of industry-sponsored research trials have a more positive attitude towards ethics committees, the quality of medical care of the research trials, and the main purpose of economical reimbursements, when compared to non-participants.

### **BMC Medicine**

<http://www.biomedcentral.com/bmcmcd/content>

(Accessed 12 Jan 2019)

*Research article*

### **[The impact of repeated vaccination on influenza vaccine effectiveness: a systematic review and meta-analysis](#)**

*Conflicting results regarding the impact of repeated vaccination on influenza vaccine effectiveness (VE) may cause confusion regarding the benefits of receiving the current season's vaccine.*

Authors: Lauren C. Ramsay, Sarah A. Buchan, Robert G. Stirling, Benjamin J. Cowling, Shuo Feng, Jeffrey C. Kwong and Bryna F. Warshawsky

Citation: BMC Medicine 2019 17:9

Published on: 10 January 2019

### **BMC Pregnancy and Childbirth**

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>  
(Accessed 12 Jan 2019)  
[No new digest content identified]

### **BMC Public Health**

<http://bmcpublichealth.biomedcentral.com/articles>  
(Accessed 12 Jan 2019)

*Research article*

#### **Maternal perceptions of childhood vaccination: explanations of reasons for and against vaccination**

*Understanding reasons for and against vaccination from the parental perspective is critical for designing vaccination campaigns and informing other interventions to increase vaccination uptake in Canada. The o...*

Authors: Deborah A. McNeil, Melissa Mueller, Shannon MacDonald, Sheila McDonald, Vineet Saini, James D. Kellner and Suzanne Tough

Citation: BMC Public Health 2019 19:49

Published on: 10 January 2019

### **BMC Research Notes**

<http://www.biomedcentral.com/bmresnotes/content>  
(Accessed 12 Jan 2019)

[No new digest content identified]

### **BMJ Open**

January 2019 - Volume 9 - 1

<http://bmjopen.bmj.com/content/current>

[Reviewed earlier]

### **Bulletin of the World Health Organization**

Volume 97, Number 1, January 2019, 1-72

<https://www.who.int/bulletin/volumes/97/1/en/>

[Reviewed earlier]

### **Child Care, Health and Development**

Volume 45, Issue 1 Pages: 1-145 January 2019

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

### **Clinical Therapeutics**

December 2018 Volume 40, Issue 12, p1957-2196

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

**Clinical Trials**

Volume 15 Issue 6, December 2018

<http://journals.sagepub.com/toc/ctja/15/6>

[Reviewed earlier]

**Conflict and Health**

<http://www.conflictandhealth.com/>

[Accessed 12 Jan 2019]

[No new digest content identified]

**Contemporary Clinical Trials**

Volume 76 Pages 1-132 (January 2019)

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/76/suppl/C>

[Reviewed earlier]

**Current Opinion in Infectious Diseases**

February 2019 - Volume 32 - Issue 1

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

**Developing World Bioethics**

Volume 18, Issue 4 Pages: 307-432 December 2018

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

**Development in Practice**

Volume 29, Issue 1, 2019

<http://www.tandfonline.com/toc/cdip20/current>

[Reviewed earlier]

**Disasters**

Volume 43, Issue 1 Pages: 1-217 January 2019

<https://onlinelibrary.wiley.com/toc/14677717/current>

[Reviewed earlier]

**EMBO Reports**

Volume 19, Number 12 01 December 2018

<http://embor.embopress.org/content/19/12?current-issue=y>

[Reviewed earlier]

### **Emerging Infectious Diseases**

Volume 25, Number 1—January 2019

<http://wwwnc.cdc.gov/eid/>

[New issue; No digest content identified]

### **Epidemics**

Volume 25 Pages 1-112 (December 2018)

<https://www.sciencedirect.com/journal/epidemics/vol/25/suppl/C>

[Reviewed earlier]

### **Epidemiology and Infection**

Volume 147 - 2019

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

*Original Paper*

#### **[Screening of more than 2000 Hungarian healthcare workers' anti-measles antibody level: results and possible population-level consequences](#)**

G. Lengyel, A. Marossy, N. Ánosi, S. L. Farkas, B. Kele, É. Nemes-Nikodém, V. Szentgyörgyi, I. Kopcsó, M. Mátyus

<https://doi.org/10.1017/S0950268818002571>

Published online: 11 September 2018, e7

#### *Abstract*

Due to the European measles epidemic and the increased number of imported cases, it can be theorised that the risk of exposure among Hungarian healthcare workers (HCWs) has increased. In 2017, the increased measles circulation in the region led to the emergence of smaller local and hospital epidemics. Therefore, our objective was to determine the herd immunity in the high-risk group of HCWs. A hospital-based study of detecting anti-measles IgG activity was performed in 2017 and included 2167 employees of the Military Medical Centre (Hungary). The screening of HCWs presented a good general seropositivity (90.6%). The highest seroprevalence value (99.1%) was found in the age group of 60 years or older. The lowest number of seropositive individuals was seen in the 41–45 years (86.2%) age group, indicating a significant herd immunity gap between groups. Regarding the Hungarian data, there might be gaps in the seroprevalence of the analysed HCWs, implying that susceptible HCWs may generate healthcare-associated infections. This study suggests that despite the extensive vaccination and high vaccine coverage, it is still important to monitor the level of protective antibodies in HCWs, or in a representative group of the whole population of Hungary, and possibly in other countries as well.

### **The European Journal of Public Health**

Volume 28, Issue 6, December 2018

<https://academic.oup.com/eurpub/issue/28/6>

[Reviewed earlier]

### **Genome Medicine**

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 24 Nov 2018]

[No new digest content identified]

### **Global Health Action**

Volume 11, 2018 – Issue 1

<https://www.tandfonline.com/toc/zgha20/11/1?nav=toCList>

[Reviewed earlier]

### **Global Health: Science and Practice (GHSP)**

Vol. 6, No. 4 December 27, 2018

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

### **Global Public Health**

Volume 14, 2019 Issue 2

<http://www.tandfonline.com/toc/rgph20/current>

[Reviewed earlier]

### **Globalization and Health**

<http://www.globalizationandhealth.com/>

[Accessed 12 Jan 2019]

[No new digest content identified]

### **Health Affairs**

Vol. 37 , No. 12 December 2018

<https://www.healthaffairs.org/toc/hlthaff/current>

#### ***Telehealth***

[Reviewed earlier]

### **Health and Human Rights**

Volume 20, Issue 2, December 2018

<https://www.hhrjournal.org/volume-20-issue-2-december-2018/>

***Issue 20.2 features a special section: Special Section on Human Rights and the Social Determinants of Health and a General Papers section***

[Reviewed earlier]

### **Health Economics, Policy and Law**

Volume 14 - Issue 1 - January 2019

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

### **Health Equity**

Volume 2, Issue 1 / December 2018

<https://www.liebertpub.com/toc/heq/2/1>

[Reviewed earlier]

### **Health Policy and Planning**

Volume 33, Issue 9, 1 November 2018

<https://academic.oup.com/heapol/issue/33/9>

[Reviewed earlier]

### **Health Research Policy and Systems**

<http://www.health-policy-systems.com/content>

[Accessed 12 Jan 2019]

*Research*

#### **[The determinants of vaccination in a semi-rural area of Vientiane City, Lao People's Democratic Republic: a qualitative study](#)**

*Immunisation is a cost-effective and highly efficacious public health intervention, saving over 20 million lives in the last two decades due to decreases in childhood bacterial infections. In the Lao People's ...*

Authors: Vanphanom Sychareun, Lucy Rowlands, Phoutsomphong Vilay, Jo Durham and Alison Morgan

Citation: Health Research Policy and Systems 2019 17:2

Published on: 9 January 2019

### **Humanitarian Exchange Magazine**

Number 73, October 2018

<https://odihpn.org/magazine/mental-health-and-psychosocial-support-in-humanitarian-crises/>

#### ***Rohingya refugees in Bangladesh: the humanitarian response***

More than 700,000 Rohingya refugees have arrived in Bangladesh since 25 August 2017 fleeing violence and persecution in Rakhine State, Myanmar. Over a million are sheltering in overcrowded camps without adequate assistance or protection. Stateless in Myanmar and denied refugee status in Bangladesh, the Rohingya have few rights or freedoms. Monsoons and cyclones are causing landslides, destroying shelters and infrastructure and disrupting services.

This edition of Humanitarian Exchange focuses on the humanitarian response to the Rohingya crisis. In the lead article, [Mark Bowden](#) outlines the historical, local and national political context in Bangladesh, and its operational implications. [Amal de Chickera](#) highlights the links between statelessness and displacement, and the international community's failure to prioritise human rights in its dealings both with Bangladesh and with Myanmar. [Puttanee Kangkun and John Quinley](#) document the persistent persecution and denial of rights the Rohingya have faced for decades. [Jeff Crisp](#) reflects on the premature, involuntary and unsafe return of Rohingya refugees to Myanmar in the 1970s and 1990s, and asks whether this could happen again.

Sally Shevach and colleagues explore how the 'localisation' agenda has influenced the operational response, and Kerrie Holloway draws on research by the Humanitarian Policy Group to test the common assumption that local actors necessarily have a better understanding of people's needs. Nasif Rashad Khan and colleagues and Ashish Banik reflect on their experiences of engaging with the international humanitarian response system. Margie Buchanan-Smith and Marian Casey-Maslen discuss evaluation findings relating to communication and community engagement, a theme taken up by Nick Van Praag and Kai Hopkins, who report on a Ground Truth survey on refugees' perceptions of assistance. Julia Brothwell discusses the British Red Cross/Bangladesh Red Crescent involvement in disaster preparedness and risk reduction during the monsoon season, and Gina Bark, Kate White and Amelie Janon outline the consequences of long-term exclusion from basic healthcare services in increasing vulnerability to preventable diseases. Matthew Wencel and colleagues round off the issue with reflections on data collection coordination and other challenges associated with monitoring large concentrations of refugees.

### **Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)

Volume 14, Issue 12, 2018

<http://www.tandfonline.com/toc/khvi20/current>

[Reviewed earlier]

### **Infectious Agents and Cancer**

<http://www.infectagentscancer.com/content>

[Accessed 12 Jan 2019]

[No new digest content identified]

### **Infectious Diseases of Poverty**

<http://www.idpjournal.com/content>

[Accessed 12 Jan 2019]

[No new digest content identified]

### **International Health**

Volume 11, Issue 1, January 2019

<http://inthehealth.oxfordjournals.org/content/current>

[Reviewed earlier]

### **International Journal of Community Medicine and Public Health**

Vol 5, No 12 (2018) December 2018

<http://www.ijcmph.com/index.php/ijcmph/issue/view/45>

[Reviewed earlier]

### **International Journal of Epidemiology**

Volume 47, Issue 6, 1 December 2018

<https://academic.oup.com/ije/issue/47/6>

[Reviewed earlier]

### **International Journal of Human Rights in Healthcare**

Volume 11 Issue 5 2018

<https://www.emeraldinsight.com/toc/ijhrh/11/5>

[Reviewed earlier]

### **International Journal of Infectious Diseases**

January 2019 Volume 78, p1-154 *Open Access*

[https://www.ijidonline.com/issue/S1201-9712\(18\)X0012-5](https://www.ijidonline.com/issue/S1201-9712(18)X0012-5)

[Reviewed earlier]

### **IRB: Ethics & Human Research**

November-December 2018 Volume: 40 Issue: 6

<https://www.thehastingscenter.org/publications-resources/irb-ethics-human-research/>

[Reviewed earlier]

### **JAMA**

January 1/8, 2019, Vol 321, No. 1, Pages 7-114

<http://jama.jamanetwork.com/issue.aspx>

[New issue; No digest content identified]

### **JAMA Pediatrics**

January 2019, Vol 173, No. 1, Pages 3-112

<http://archpedi.jamanetwork.com/issue.aspx>

*Viewpoint*

#### **[Human Papillomavirus Vaccination and School Entry Requirements Politically Challenging, but Not Impossible](#)**

Ellen Daley, PhD, MPH; Erika Thompson, PhD, MPH; Gregory Zimet, PhD

JAMA Pediatr. 2019;173(1):6-7. doi:10.1001/jamapediatrics.2018.3327

This Viewpoint promotes implementing state-level school entry requirements for the human papillomavirus vaccine for US adolescents.

#### **[Participant Protection in Phase 1 Pediatric Cancer Trials](#)**

Jonathan Kimmelman, PhD; Marcin Waligora, PhD; Holly Fernandez Lynch, JD, MBE

JAMA Pediatr. 2019;173(1):8-9. doi:10.1001/jamapediatrics.2018.3629

This Viewpoint describes changes in the regulatory environment for phase 1 research involving children and discusses improvements to patient protection.

*Original Investigation*

#### **[Duration of Pediatric Clinical Trials Submitted to the US Food and Drug Administration](#)**



Kanecia O. Zimmerman, MD, MPH; P. Brian Smith, MD, MPH, MHS; Ann W. McMahon, MD, MS; et al.

JAMA Pediatr. 2019;173(1):60-67. doi:10.1001/jamapediatrics.2018.3227

This study characterizes the duration of clinical trials submitted to the US Food and Drug Administration for pediatric drug approvals, with a focus on drugs used for long-term therapy.

**[Safety and Immunogenicity of Early Bacillus Calmette-Guérin Vaccination in Infants Who Are Preterm and/or Have Low Birth Weights- A Systematic Review and Meta-analysis](#)**

Shiraz Badurdeen, MRCPCH; Andrew Marshall, DPhil; Hazel Daish, MRCPCH; et al.  
open access

JAMA Pediatr. 2019;173(1):75-85. doi:10.1001/jamapediatrics.2018.4038

This systematic review and meta-analysis examines the safety and efficacy of bacillus Calmette-Guérin vaccination at birth or later points in infants who are preterm and/or had low birth weights compared with ones who are full term and/or had normal birth weights.

**JBI Database of Systematic Review and Implementation Reports**

January 2019 - Volume 17 - Issue 1

<http://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[New issue; No digest content identified]

**Journal of Adolescent Health**

January 2019 Volume 64, Issue 1, p1-140

[https://www.jahonline.org/issue/S1054-139X\(17\)X0016-5](https://www.jahonline.org/issue/S1054-139X(17)X0016-5)

[Reviewed earlier]

**Journal of Community Health**

Volume 44, Issue 1, February 2019

<https://link.springer.com/journal/10900/44/1>

*Original Paper*

**[Social Determinants of Health and Human Papillomavirus Vaccination Among Young Adults, National Health Interview Survey 2016](#)**

Erika L. Thompson, Brittany L. Rosen, Sarah B. Maness

**Journal of Empirical Research on Human Research Ethics**

Volume 13 Issue 5, December 2018

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

**Journal of Epidemiology & Community Health**

January 2019 - Volume 73 - 1

<https://jech.bmj.com/content/73/1>

[Reviewed earlier]

**Journal of Evidence-Based Medicine**

Volume 11, Issue 4 Pages: 217-291 November 2018  
<https://onlinelibrary.wiley.com/toc/17565391/current>  
[Reviewed earlier]

**Journal of Global Ethics**

Volume 14, Issue 2, 2018  
<http://www.tandfonline.com/toc/rjge20/current>  
***Special Issue: Reconciliation, Transitional and Indigenous Justice***  
[Reviewed earlier]

**Journal of Health Care for the Poor and Underserved (JHCPU)**

Volume 29, Number 4, November 2018  
<https://muse.jhu.edu/issue/39355>  
[Reviewed earlier]

**Journal of Immigrant and Minority Health**

Volume 20, Issue 6, December 2018  
<https://link.springer.com/journal/10903/20/6/page/1>  
[Reviewed earlier]

**Journal of Immigrant & Refugee Studies**

Volume 16, 2018\_ Issue 4  
<http://www.tandfonline.com/toc/wimm20/current>  
[Reviewed earlier]

**Journal of Infectious Diseases**

Volume 217, Issue 11, 12 Jan 2019  
<https://academic.oup.com/jid/issue/217/1>  
[Reviewed earlier]

**Journal of Medical Ethics**

January 2019 - Volume 45 - 1  
<http://jme.bmj.com/content/current>  
[Reviewed earlier]

**Journal of Medical Internet Research**

Vol 20, No 12 (2018): December  
<https://www.jmir.org/2018/12>

[Reviewed earlier]

**Journal of Medical Microbiology**

Volume 67, Issue 12, December 2018

<https://jmm.microbiologyresearch.org/content/journal/jmm/67/12>

[Reviewed earlier]

**Journal of Patient-Centered Research and Reviews**

Volume 5, Issue 4 (2018)

<https://digitalrepository.aurorahealthcare.org/jpcrr/>

[Reviewed earlier]

**Journal of the Pediatric Infectious Diseases Society (JPIDS)**

Volume 7, Issue 4, December 2018

<https://academic.oup.com/jpids/issue>

[Reviewed earlier]

**Journal of Pediatrics**

January 2019 Volume 204, p1-330

<http://www.jpeds.com/current>

[New issue; No digest content identified]

**Journal of Pharmaceutical Policy and Practice**

<https://joppp.biomedcentral.com/>

[Accessed 12 Jan 2019]

No new digest content identified]

**Journal of Public Health Management & Practice**

January/February 2019 - Volume 25 - Issue 1

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

**Journal of Public Health Policy**

Volume 39, Issue 4, November 2018

<https://link.springer.com/journal/41271/39/4/page/1>

[Reviewed earlier]

**Journal of the Royal Society – Interface**

2 January 2019 Volume 16 Issue 150

<https://royalsocietypublishing.org/journal/rsif>

[New issue; No digest content identified]

**Journal of Travel Medicine**

Volume 25, Issue suppl\_1, 1 May 2018

[https://academic.oup.com/jtm/issue/25/suppl\\_1](https://academic.oup.com/jtm/issue/25/suppl_1)

***Asian travel: from the rare to the difficult***

[Reviewed earlier]

**Journal of Virology**

December 2018; Volume 92, Issue 24

<http://jvi.asm.org/content/current>

[Reviewed earlier]

**The Lancet**

Jan 12, 2019 Volume 393 Number 10167 p103-198

<https://www.thelancet.com/journals/lancet/issue/current>

*Comment*

**[Health-emergency disaster risk management and research ethics](#)**

Emily Y Y Chan, Katharine Wright, Michael Parker

**Lancet Global Health**

Jan 2019 Volume 7 Number 1 e1-e159

<http://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

**Lancet Infectious Diseases**

Jan 2019 Volume 19 Number 1 p1-112, e1-e38

<http://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

**Lancet Respiratory Medicine**

Jan 2019 Volume 7 Number 1 p1-98, e1

<http://www.thelancet.com/journals/lanres/issue/current>

[Reviewed earlier]

**Maternal and Child Health Journal**

Volume 23, Issue 1, January 2019

<https://link.springer.com/journal/10995/22/12/page/1>

[New issue; No digest content identified]

## **Medical Decision Making (MDM)**

Volume 39 Issue 1, January 2019

<http://mdm.sagepub.com/content/current>

[New issue; No digest content identified]

## **The Milbank Quarterly**

*A Multidisciplinary Journal of Population Health and Health Policy*

Volume 96, Issue 4 Pages: 607-882 December 2018

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

## **Nature**

Volume 565 Issue 7738, 10 January 2019

[http://www.nature.com/nature/current\\_issue.html](http://www.nature.com/nature/current_issue.html)

*World View* | 02 January 2019

### **[Human genome editing: ask whether, not how](#)**

The scientific community's response to the CRISPR twins should not pre-empt broader discussion across society, warns J. Benjamin Hurlbut.

J. Benjamin Hurlbut

*Letter* | 02 January 2019

### **[Genomic insights into the 2016–2017 cholera epidemic in Yemen](#)**

Isolates of the *Vibrio cholerae* O1 serotype Ogawa from Yemen are from a single sublineage of the seventh pandemic El Tor (7PET) lineage and are susceptible to several commonly used antibiotics as well as to polymyxins.

François-Xavier Weill, Daryl Domman [...] & Marie-Laure Quilici

*Letter* | 19 December 2018

### **[Actively personalized vaccination trial for newly diagnosed glioblastoma](#)**

In a phase I trial, highly individualized peptide vaccines against unmutated tumour antigens and neoepitopes elicited sustained responses in CD8+ and CD4+ T cells, respectively, in patients with newly diagnosed glioblastoma.

Norbert Hilf, Sabrina Kuttruff-Coqui [...] & Wolfgang Wick

## **Nature Medicine**

Volume 25 Issue 1, January 2019

<https://www.nature.com/nm/volumes/24/issues/12>

### ***Medicine in the digital age***

As *Nature Medicine* celebrates its 25th anniversary, we bring our readers a special Focus on Digital Medicine that highlights the new technologies transforming medicine and healthcare, as well as the related regulatory challenges ahead.

*Editorial* | 07 January 2019

### **[Medicine in the digital age](#)**

As Nature Medicine celebrates its 25th anniversary, we bring you a special Focus on Digital Medicine that highlights the new technologies transforming medicine and healthcare, as well as the related regulatory challenges ahead.

*News Feature* | 07 January 2018

**[Twenty-five ways clinical trials have changed in the last 25 years](#)**

Exploring the evolution, from analysis and endpoints to registration and regulations  
Mike May

*Review Article* | 07 January 2019

**[Privacy in the age of medical big data](#)**

The increased amount of health care data collected brings with it ethical and legal challenges for protecting the patient while optimizing health care and research.  
W. Nicholson Price II & I. Glenn Cohen

**Nature Reviews Immunology**

Volume 19 Issue 1, January 2019

<https://www.nature.com/nri/volumes/19/issues/1>

[Reviewed earlier]

**New England Journal of Medicine**

January 10, 2019 Vol. 380 No. 2

<http://www.nejm.org/toc/nejm/medical-journal>

*Perspective*

**[Disease and Famine as Weapons of War in Yemen](#)**

Amir M. Mohareb, M.D.,  
and Louise C. Ivers, M.D., M.P.H., D.T.M.&H.

*Audio Interview*

*[Interview with Dr. Amir Mohareb on the humanitarian crisis and violations of medical neutrality in Yemen. \(10:45\)Download](#)*

The infliction of suffering in the war in Yemen has particularly toxic characteristics that demand attention from health care providers worldwide: the destruction of health care facilities and the spread of disease and hunger as apparent means of waging war.

**Pediatrics**

January 2019, VOLUME 143 / ISSUE 1

<http://pediatrics.aappublications.org/content/143/1?current-issue=y>

[Reviewed earlier]

**Pharmaceutics**

Volume 10, Issue 4 (December 2018)

<https://www.mdpi.com/1999-4923/10/4>

[New issue; No digest content identified]

## **PharmacoEconomics**

Volume 36, Issue 12, December 2018

<https://link.springer.com/journal/40273/36/12/page/1>

[Reviewed earlier]

## **PharmacoEconomics & Outcomes News**

Volume 817, Issue 1, December 2018

<https://link.springer.com/journal/40274/817/1/page/1>

[Reviewed earlier]

## **PLOS Currents: Disasters**

<http://currents.plos.org/disasters/>

[Accessed 12 Jan 2019]

[No new digest content identified]

## **PLoS Currents: Outbreaks**

<http://currents.plos.org/outbreaks/>

[Accessed 12 Jan 2019]

[No new digest content identified]

## **PLoS Medicine**

<http://www.plosmedicine.org/>

(Accessed 12 Jan 2019)

[No new digest content identified]

## **PLoS Neglected Tropical Diseases**

<http://www.plosntds.org/>

(Accessed 12 Jan 2019)

### **[Economic burden of dengue in Indonesia](#)**

Mardiati Nadjib, Ery Setiawan, Septiara Putri, Joshua Nealon, Sophie Beucher, Sri Rezeki Hadinegoro, Vetty Yulianty Permanasari, Kurnia Sari, Tri Yunis Miko Wahyono, Erna Kristin, Dewa Nyoman Wirawan, Hasbullah Thabrany

Research Article | published 10 Jan 2019 PLOS Neglected Tropical Diseases

<https://doi.org/10.1371/journal.pntd.0007038>

*Abstract*

Background

Dengue is associated with significant economic expenditure and it is estimated that the Asia Pacific region accounts for >50% of the global cost. Indonesia has one of the world's highest dengue burdens; *Aedes aegypti* and *Aedes albopictus* are the primary and secondary vectors. In the absence of local data on disease cost, this study estimated the annual economic burden during 2015 of both hospitalized and ambulatory dengue cases in Indonesia.

Methods

Total 2015 dengue costs were calculated using both prospective and retrospective methods using data from public and private hospitals and health centres in three provinces: Yogyakarta, Bali and Jakarta. Direct costs were extracted from billing systems and claims; a patient survey captured indirect and out-of-pocket costs at discharge and 2 weeks later. Adjustments across sites based on similar clinical practices and healthcare landscapes were performed to fill gaps in cost estimates. The national burden of dengue was extrapolated from provincial data using data from the three sites and applying an empirically-derived epidemiological expansion factor.

#### Results

Total direct and indirect costs per dengue case assessed at Yogyakarta, Bali and Jakarta were US\$791, US\$1,241 and US\$1,250, respectively. Total 2015 economic burden of dengue in Indonesia was estimated at US\$381.15 million which comprised US\$355.2 million for hospitalized and US\$26.2 million for ambulatory care cases.

#### Conclusion

Dengue imposes a substantial economic burden for Indonesian public payers and society. Complemented with an appropriate weighting method and by accounting for local specificities and practices, these data may support national level public health decision making for prevention/control of dengue in public health priority lists.

#### *Author summary*

Dengue, an infection transmitted by mosquitos, is a public health concern particularly in tropical/subtropical areas and the Asia Pacific region where it is associated with a significant cost to society. Indonesia has one of the world's highest dengue burdens but Indonesia-specific data on cost are lacking. To estimate the annual economic burden of dengue in Indonesia, this study collected data from public/private hospitals and health centres in three provinces (Yogyakarta, Bali and Jakarta) during 2015. We estimated cost of illness using the societal perspective: calculations of costs included those that were directly paid by the healthcare system, as well as costs incurred by the patients (or their family/care givers) and their lost productivity. The costs from the three provinces were then used as the basis for extrapolating cost of illness in Indonesia. The authors confirmed that dengue imposed a substantial economic burden for Indonesian public payers and society. Based on 2015 data, the authors estimated total economic burden of dengue in Indonesia at US\$381.15 million. Of this, US\$355.2 million related to patients treated in hospitals and US\$26.2 million was for patients treated in health centres. Establishing a better understanding of the burden of dengue in Indonesia will help to guide public health decision-making at a national level and support prevention and control initiatives for this disease.

#### **PLoS One**

<http://www.plosone.org/>

[Accessed 12 Jan 2019]

*Research Article*

**[Involving patients and the public in medical and health care research studies: An exploratory survey on participant recruiting and representativeness from the perspective of study authors](#)**

Jonas Lander, Holger Langhof, Marie-Luise Dierks

Research Article | published 07 Jan 2019 PLOS ONE

<https://doi.org/10.1371/journal.pone.0204187>

*Abstract*



Research on patient and public involvement so far concentrates on defining involvement, describing its methods, and analyzing involvement practices in various individual research disciplines. There is little empirical data on the process of and aims for selecting (lay) PPI participants, and to what extent they can and should be representative of the population at large. To explore practices and perceptions on these issues and on future PPI conduct more generally, we sent an electronic survey to authors who published involvement activities as part of their studies in medical and social science journals. We identified such authors with a systematic search of five databases and applied descriptive statistics for analysis. Of those who returned the survey (n = 127 of 315; 40%), most had previously conducted involvement activities (73%). 45% reported more than one type of involvement, e.g. consultation and deliberation and participation (14%) and to have recruited more than one type of participant for their PPI activity (56%), e.g. 'lay publics' and 'expert publics' (33% of 71). Representativeness was often seen as a crucial objective when selecting PPI participants, while less than half found it very easy (9%) or rather easy (34%) to select participants. Many respondents considered achieving good representativeness difficult (52%) or very difficult (17%). They identified significant respective challenges and desired more guidance on various aspects of planning and conducting PPI (56%). 55% thought that the concept of "involvement" should be changed or improved. We conclude that recruiting lay people for PPI activities and deciding about and handling representativeness are controversial in current PPI practice, given the manifold challenges mentioned by the survey respondents. Our findings may inform further research particularly regarding—the potentially many cases of—unpublished PPI.

#### *Research Article*

### **[Resource use, costs, and approval times for planning and preparing a randomized clinical trial before and after the implementation of the new Swiss human research legislation](#)**

Benjamin Speich, Nadine Schur, Dmitry Gryaznov, Belinda von Niederhäusern, Lars G. Hemkens, Stefan Schandelmaier, Alain Amstutz, Benjamin Kasenda, Christiane Pauli-Magnus, Elena Ojeda-Ruiz, Yuki Tomonaga, Kimberly McCord, Alain Nordmann, Erik von Elm, Matthias Briel, Matthias Schwenkglenks, a collaboration of the MARTA (MAKING Randomized Trials Affordable) and ASPIRE (Adherence to Standard Protocol Items: REcommendations for interventional trials) Study Groups

Research Article | published 11 Jan 2019 PLOS ONE

<https://doi.org/10.1371/journal.pone.0210669>

### **[Invasive pneumococcal diseases in children and adults before and after introduction of the 10-valent pneumococcal conjugate vaccine into the Austrian national immunization program](#)**

Lukas Richter, Daniela Schmid, Elisabeth Eva Kanitz, Ines Zwazl, Eva Pöllabauer, Joanna Jasinska, Heinz Burgmann, Michael Kundi, Ursula Wiedermann

Research Article | published 10 Jan 2019 PLOS ONE

<https://doi.org/10.1371/journal.pone.0210081>

### **[Facilitators and barriers for healthcare providers to recommend HPV vaccination to attendees of public sexually transmitted diseases clinics in Hong Kong, China](#)**

Ying Ying Lee, Zixin Wang

Research Article | published 09 Jan 2019 PLOS ONE

<https://doi.org/10.1371/journal.pone.0209942>

**PLoS Pathogens**

<http://journals.plos.org/plospathogens/>

[Accessed 12 Jan 2019]

[No new digest content identified]

**PNAS - Proceedings of the National Academy of Sciences of the United States of America**

<http://www.pnas.org/content/early/>

[Accessed 12 Jan 2019]

[No new digest content identified]

**Prehospital & Disaster Medicine**

Volume 33 - Issue 6 - December 2018

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

**Preventive Medicine**

Volume 118 Pages 1-354 (January 2019)

<https://www.sciencedirect.com/journal/preventive-medicine/vol/117/suppl/C>

[Reviewed earlier]

**Proceedings of the Royal Society B**

29 August 2018; volume 285, issue 1885

<http://rspb.royalsocietypublishing.org/content/285/1885?current-issue=y>

[Reviewed earlier]

**Public Health**

Volume 166 Pages 1-154, A1-A4 (January 2019)

<http://www.publichealthjrnل.com/current>

[New issue; No digest content identified]

**Public Health Ethics**

Volume 11, Issue 3, November 2018

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

**Public Health Reports**

Volume 133 Issue 1\_suppl, November/December 2018

[https://journals.sagepub.com/toc/phrg/133/1\\_suppl](https://journals.sagepub.com/toc/phrg/133/1_suppl)

***From Local Action to National Progress on 5 Major Health Challenges: The Bloomberg American Health Initiative***

Guest Editor: Joshua M. Sharfstein, Jessica Leighton, Alfred Sommer and Ellen J. MacKenzie  
[Reviewed earlier]

**Qualitative Health Research**

Volume 29 Issue 2, January 2019  
<http://qhr.sagepub.com/content/current>  
[Reviewed earlier]

**Research Ethics**

Volume 14 Issue 4, October 2018  
<http://journals.sagepub.com/toc/reab/current>  
[Reviewed earlier]

**Reproductive Health**

<http://www.reproductive-health-journal.com/content>  
[Accessed 12 Jan 2019]  
[No new digest content identified]

**Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)**

[http://www.paho.org/journal/index.php?option=com\\_content&view=featured&Itemid=101](http://www.paho.org/journal/index.php?option=com_content&view=featured&Itemid=101)  
*Recently Published Articles*  
[No new digest content identified]

**Risk Analysis**

Volume 39, Issue 1 Pages: 1-290 January 2019  
<https://onlinelibrary.wiley.com/toc/15396924/current>  
***Advances in Spatial Risk Analysis***  
[Reviewed earlier]

**Risk Management and Healthcare Policy**

Volume 11, 2018  
<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>  
[No new digest content identified]

**Science**

11 January 2019 Vol 363, Issue 6423  
<http://www.sciencemag.org/current.dtl>  
[New issue; No digest content identified]

## **Science Translational Medicine**

09 January 2019 Vol 11, Issue 474

<http://stm.sciencemag.org/>

*Review*

### **[Challenges and strategies for developing efficacious and long-lasting malaria vaccines](#)**

By James G. Beeson, Liriye Kurtovic, Carlota Dobaño, D. Herbert Opi, Jo-Anne Chan, Gaoqian Feng, Michael F. Good, Linda Reiling, Michelle J. Boyle

Science Translational Medicine 09 Jan 2019 Restricted Access

*New knowledge and strategies are emerging to enable the development of an efficacious and long-lasting vaccine against malaria.*

*Abstract*

Although there has been major recent progress in malaria vaccine development, substantial challenges remain for achieving highly efficacious and durable vaccines against *Plasmodium falciparum* and *Plasmodium vivax* malaria. Greater knowledge of mechanisms and key targets of immunity are needed to accomplish this goal, together with new strategies for generating potent, long-lasting, functional immunity against multiple antigens. Implementation considerations in endemic areas will ultimately affect vaccine effectiveness, so innovations to simplify and enhance delivery are also needed. Whereas challenges remain, recent exciting progress and emerging knowledge promise hope for the future of malaria vaccines.

## **Social Science & Medicine**

Volume 220 Pages 1-450 (January 2019)

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/220/suppl/C>

[Reviewed earlier]

## **Systematic Reviews**

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 12 Jan 2019]

*Protocol*

### **[Protocol for a systematic review of the effects of interventions for vaccine stock management](#)**

*Inadequate vaccine stock management in health facilities leads to vaccine stock-outs. The latter threatens the success of immunisation programmes. Countries have used various approaches to reduce stock-outs an...*

Authors: Chinwe Juliana Iwu, Anelisa Jaca, Leila H. Abdullahi, Ntombenhle Judith Ngcobo and Charles Shey Wiysonge

Citation: Systematic Reviews 2019 8:14

Published on: 8 January 2019

## **Travel Medicine and Infectious Diseases**

Volume 26 Pages 1-78 (November–December 2018)

<http://www.travelmedicinejournal.com/>

[Reviewed earlier]

## **Tropical Medicine & International Health**

Volume 24, Issue 1 Pages: i-iv, 1-129 January 2019

<https://onlinelibrary.wiley.com/toc/13653156/current>

[New issue; No digest content identified]

## **Vaccine**

Volume 37, Issue 4 Pages 539-676 (21 January 2019)

<https://www.sciencedirect.com/journal/vaccine/vol/37/issue/4>

*Review article Open access*

### **[Would immunization be the same without cross-reactivity?](#)**

Ivo Vojtek, Philippe Buchy, T. Mark Doherty, Bernard Hoet

Pages 539-549

Abstract

“Cross-reactivity” (the observed immune response against pathogen types not specifically targeted by the vaccine antigen composition) and “cross-protection” (clinical protection against related non-vaccine microorganism types) are vaccinology concepts that are attracting renewed interest in the context of disease prevention. National health authorities are collecting mounting evidence of the importance of cross-reactivity. For some vaccines, this has been substantiated by cross-protection data from clinical studies and/or post-licensure data, where their introduction into immunization programmes has shown beneficial impacts on disease caused by related non-vaccine microorganisms. This knowledge has influenced the way new vaccines are designed, developed, and evaluated in real-life settings. Some of the new vaccines are now designed with the specific aim of having a greater breadth of protection. Ideal vaccine antigens therefore include epitopes with conserved homology across related pathogen types, because it is not always possible to include the antigens of all the individual types of a given pathogen species. The use of novel adjuvants with greater immunostimulatory properties can also contribute to improved overall vaccine cross-reactivity, as could the use of antigen delivery platforms. The growing body of evidence allows us to better understand the full impact of vaccines – beyond vaccine-type disease – which should be taken into consideration when assessing the full value of vaccination programmes.

*Research article Abstract only*

### **[HPV vaccination, knowledge, and attitudes among young cervical cancer survivors in the Deep South](#)**

M. Edler, A. Fernandez, K. Anderson, J.Y. Pierce, ... C.L. Daniel

Pages 550-557

*Research article Abstract only*

### **[Assessing the timeliness of vaccine administration in children under five years in India, 2013](#)**

Abram L. Wagner, Luke M. Shenton, Brenda W. Gillespie, Joseph L. Mathew, Matthew L. Boulton

Pages 558-564

*Research article Abstract only*

**Variations in reason for intention not to vaccinate across time, region, and by race/ethnicity, NIS-Teen (2008–2016)**

Jacqueline M. Hirth, Erika L. Fuchs, Mihyun Chang, Maria E. Fernandez, Abbey B. Berenson  
Pages 595-601

*Research article Abstract only*

**Impact and cost effectiveness of pneumococcal conjugate vaccine in India**

Yuvaraj Krishnamoorthy, Salin K. Elias, Nayana P. Nair, Manikandanesan Sakthivel, ... Palanivel Chinnakali  
Pages 623-630

*Research article Abstract only*

**The potential effects of introducing microneedle patch vaccines into routine vaccine supply chains**

Patrick T. Wedlock, Elizabeth A. Mitgang, Fayad Elsheikh, Jim Leonard, ... Bruce Y. Lee  
Pages 645-651

*Research article Open access*

**Parental awareness of Meningococcal B vaccines and willingness to vaccinate their teens**

Nicole E. Basta, Andrew B. Becker, Qingxiao Li, Dawn Nederhoff  
Pages 670-676

**Vaccine: Development and Therapy**

<https://www.dovepress.com/vaccine-development-and-therapy-archive111>

(Accessed 12 Jan 2019)

[No new digest content identified]

**Vaccines — Open Access Journal**

<http://www.mdpi.com/journal/vaccines>

(Accessed 12 Jan 2019)

[No new digest content identified]

**Value in Health**

December 2018 Volume 21, Issue 12, p1355-1444

<http://www.valueinhealthjournal.com/current>

[Reviewed earlier]

**Viruses**

2018, 10 (12) (December 2018)

<https://www.mdpi.com/1999-4915/10/12>

[Reviewed earlier]

\* \* \* \*

**From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary**

**Frontiers in Immunology**

2019 doi: 10.3389/fimmu.2019.00008

**Strategies to Improve Cancer Vaccine Efficacy**

K Vermaelen -

More than many other fields in medicine, cancer vaccine development has been plagued by a wide gap between the massive amounts of highly encouraging preclinical data on one hand, and the disappointing clinical results on the other. It is clear now that traditional approaches from the infectious diseases' vaccine field cannot be borrowed as such to treat cancer.

In this review we will highlight some of the strategies developed to improve vaccine formulations for oncology, including research into more powerful or "smarter" adjuvants to elicit anti-tumoral cellular immune responses.

As an illustration of the difficulties in translating smart preclinical strategies into real benefit for the cancer patient, we will discuss the difficult road of vaccine development in lung cancer is given as example.

Finally, an outline is provided of we will provide an overview of the combinatorial strategies that leverage the increasing knowledge on tumor-associated immune suppressive networks. Indeed, combining with drugs that target the dominant immunosuppressive pathway in a given tumor promises to will unlock the true power of cancer vaccines and potentially offer long-term protection from disease relapse.

\* \* \* \*

**Media/Policy Watch**

This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. *Media Watch* is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from *Journal Watch* above which scans the peer-reviewed journal ecology.

We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.

**The Atlantic**

<http://www.theatlantic.com/magazine/>

*Accessed 12 Jan 2019*

[No new, unique, relevant content]

### **BBC**

<http://www.bbc.co.uk/>

*Accessed 12 Jan 2019*

[No new, unique, relevant content]

### **The Economist**

<http://www.economist.com/>

*Accessed 12 Jan 2019*

[No new, unique, relevant content]

### **Financial Times**

<http://www.ft.com/home/uk>

*Accessed 12 Jan 2019*

[No new, unique, relevant content]

### **Forbes**

<http://www.forbes.com/>

*Accessed 12 Jan 2019*

[No new, unique, relevant content]

### **Foreign Affairs**

<http://www.foreignaffairs.com/>

*Accessed 12 Jan 2019*

[No new, unique, relevant content]

### **Foreign Policy**

<http://foreignpolicy.com/>

*Accessed 12 Jan 2019*

[No new, unique, relevant content]

### **The Guardian**

<http://www.guardiannews.com/>

*Accessed 12 Jan 2019*

[No new, unique, relevant content]

### **New Yorker**

<http://www.newyorker.com/>

*Accessed 12 Jan 2019*

[No new, unique, relevant content]

### **New York Times**

<http://www.nytimes.com/>

*Accessed 12 Jan 2019*

[No new, unique, relevant content]



## Wall Street Journal

<http://online.wsj.com/home-page? wsjregion=na,us& homepage=/home/us>

*Accessed 12 Jan 2019*

[No new, unique, relevant content]

## Washington Post

<http://www.washingtonpost.com/>

*Accessed 12 Jan 2019*

*Opinions*

### **[Italy's right wing is waging a dangerous attack on vaccinations](#)**

Michael Gerson · Dec 10, 2018

... Italy's right-wing coalition government — composed of conservatives and Internet-based populists (including former communists) — has provided a political home for the anti-vaccination movement. The hard core of that movement, according to public-health surveys, is quite small. But its arguments reinforce the questions and fears of a broader 15 to 20 percent of the Italian population who are seriously hesitant about vaccination.

A 2017 Italian law expanding the number of mandatory vaccinations from four to 10 produced significantly greater coverage, as well as a populist backlash. Italy's new interior minister has said the requirements are "useless and in many cases dangerous." One senator from the government coalition has compared vaccination scars to "branding for beasts." The new health minister recently sacked the government's entire, 30-member science advisory panel, presumably to obtain advice more amenable to populist ideology.

The arguments of the Italian anti-vaccination movement are the same as elsewhere. Its members believe vaccinations are somehow associated with either autism, tumors or allergies. Since there is no reputable science to support this view — none at all — they turn to the language of parental choice and "more freedom" for families in health care. And they often add a conspiratorial element, accusing Big Pharma of making a profit from unnecessary vaccinations...

\* \* \* \*

## **[Think Tanks et al](#)**

### Brookings

<http://www.brookings.edu/>

*Accessed 12 Jan 2019*

[No new relevant content]

### Center for Global Development

<http://www.cgdev.org/page/press-center>

[No new relevant content]

### CSIS

<https://www.csis.org/>

*Accessed 12 Jan 2019*

[No new relevant content]

### Council on Foreign Relations

<http://www.cfr.org/>

Accessed 12 Jan 2019

[No new relevant content]

\* \* \* \*  
\* \* \* \*

***Vaccines and Global Health: The Week in Review*** is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global, which is solely responsible for its content, and is an open access publication, subject to the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by-nc/3.0/>). Copyright is retained by CVEP.

*CVEP is a program of the GE2P2 Global Foundation – whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances. CVEP maintains an academic affiliation with the Division of Medical Ethics, NYU School of Medicine, and an operating affiliation with the Vaccine Education Center of Children’s Hospital of Philadelphia [CHOP].*

*Support for this service is provided by the Bill & Melinda Gates Foundation; Aeras; PATH, and industry resource members Janssen/J&J, Pfizer, Sanofi Pasteur U.S., Takeda, Moderna Therapeutics (list in formation), and the Developing Countries Vaccine Manufacturers Network (DCVMN).*

*Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.*

\* \* \* \*  
\* \* \* \*